Reacciones adversas reportadas por Golimumab al Programa Distrital de Farmacovigilancia en Bogotá D.C en el periodo 2012-2016
The analysis of adverse drug reactions (ADR), an activity performed in the pharmacovigilance program is of great importance in the pharmaceutical field, from the knowledge of these reactions it is possible to prevent, to provide safety, quality and efficacy in the treatment of patients Through the r...
- Autores:
-
Turriago García, Astrid Yineth
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2017
- Institución:
- Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
- Repositorio:
- Repositorio Institucional UDCA
- Idioma:
- spa
- OAI Identifier:
- oai:repository.udca.edu.co:11158/862
- Acceso en línea:
- https://repository.udca.edu.co/handle/11158/862
- Palabra clave:
- Golimumab
Farmacovigilancia-RAM
Programa Distrital de Farmacovigilancia -- Bogotá (Colombia)
Golimumab -- Efectos secundarios
Medicamentos -- Efectos secundarios
- Rights
- closedAccess
- License
- Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
| Summary: | The analysis of adverse drug reactions (ADR), an activity performed in the pharmacovigilance program is of great importance in the pharmaceutical field, from the knowledge of these reactions it is possible to prevent, to provide safety, quality and efficacy in the treatment of patients Through the respective evaluation and analysis for each reported event, contributing to the implementation of preventive and corrective actions in the people treated. In this study adverse drug reactions were reported between 2012-2016 for the biological drug Golimumab from the database of the District Pharmacovigilance Program in Bogota DC, evidencing Suspected adverse drug reactions (SRAM), problems related to Medications (PRM), determination of severity and causality that affect the clinical situation, among other parameters |
|---|